ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 029,36
0,29%
Dow Jones
44 494,01
0,05%
DAX
22 018,01
0,39%
Brent Oil
76,675
0,99%
Bitcoin
97 028,30
-0,47%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. L'Europe
  5. EU
  6. Galapagos (GLPG)

  7. Galapagos (GLPG) Actualités

GLPG

Galapagos (GLPG)

Galapagos
De:
Trier par:
 Showing the most relevant articles for your search:EU:GLPG
DateHeureSourceTitreSymboleSociété
08/01/202507h30GlobeNewswire Inc.Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded EntitiesEU:GLPGGalapagos
07/01/202522h01GlobeNewswire Inc.Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceEU:GLPGGalapagos
07/12/202418h30GlobeNewswire Inc.Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin LymphomaEU:GLPGGalapagos
05/11/202422h01GlobeNewswire Inc.Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024EU:GLPGGalapagos
30/10/202421h01GlobeNewswire Inc.Galapagos Reports Third Quarter 2024 Financial Results and Provides Business UpdateEU:GLPGGalapagos
07/10/202407h00GlobeNewswire Inc.Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growthEU:GLPGGalapagos
30/09/202422h01GlobeNewswire Inc.Galapagos receives transparency notification from EcoR1 CapitalEU:GLPGGalapagos
03/09/202422h01GlobeNewswire Inc.Galapagos receives transparency notification from FMR LLCEU:GLPGGalapagos
23/08/202407h00GlobeNewswire Inc.Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphomaEU:GLPGGalapagos
01/08/202422h01GlobeNewswire Inc.Galapagos reports half-year 2024 financial results and provides second quarter business updateEU:GLPGGalapagos
14/06/202422h01GlobeNewswire Inc.Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024EU:GLPGGalapagos
30/05/202422h01GlobeNewswire Inc.Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsEU:GLPGGalapagos
16/05/202422h01GlobeNewswire Inc.Galapagos creates new subscription right plansEU:GLPGGalapagos
15/05/202422h01GlobeNewswire Inc.Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.EU:GLPGGalapagos
02/05/202422h01GlobeNewswire Inc.Galapagos reports first quarter 2024 financial results  EU:GLPGGalapagos
30/04/202422h01GlobeNewswire Inc.Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024EU:GLPGGalapagos
04/04/202422h01GlobeNewswire Inc.Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024EU:GLPGGalapagos
28/03/202421h01GlobeNewswire Inc.Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsEU:GLPGGalapagos
26/03/202421h01GlobeNewswire Inc.Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its BoardEU:GLPGGalapagos
22/02/202422h01GlobeNewswire Inc.Galapagos announces full year 2023 results and outlook for 2024EU:GLPGGalapagos
15/02/202422h01GlobeNewswire Inc.Galapagos presents at EBMT-EHA annual meeting 2024EU:GLPGGalapagos
31/01/202422h01GlobeNewswire Inc.Galapagos completes transaction to transfer Jyseleca® business to AlfasigmaEU:GLPGGalapagos
04/01/202422h44Dow Jones NewsGalapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer DrugEU:GLPGGalapagos
04/01/202422h01GlobeNewswire Inc.Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.EU:GLPGGalapagos
03/01/202422h01GlobeNewswire Inc.Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncologyEU:GLPGGalapagos
02/01/202407h00GlobeNewswire Inc.Galapagos signs agreement to transfer Jyseleca® business to AlfasigmaEU:GLPGGalapagos
19/12/202322h01GlobeNewswire Inc.Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301EU:GLPGGalapagos
09/12/202318h00GlobeNewswire Inc.Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101EU:GLPGGalapagos
07/12/202322h01GlobeNewswire Inc.Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023EU:GLPGGalapagos
02/11/202321h01GlobeNewswire Inc.Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023EU:GLPGGalapagos
 Showing the most relevant articles for your search:EU:GLPG

Dernières Valeurs Consultées

BIT
NSCIT5583413
Intesa Sanpaolo
BIT
NSCIT35087F8
Canada
BIT
NSCIT000A2W6
Austria
BIT
NSCIT0542257
InnovativeRFK
BIT
UC92UM
Unicredit Bank
BIT
USSMC
ETF
BIT
NSCIT2107448
IBRD
BIT
NSCIT0497650
Italy
BIT
NSCIT1380384
Kred F Wied 01/32 Mtn
BIT
NSCIT5365316
Imi Fabi
BIT
UC8FS4
Unicredit Bank
BIT
I08159
Intesa Sanpaolo
BIT
S29016
Societe Generale Effekten
BIT
I07027
INTESA SANPAOLO
BIT
S24906
SG ISSUER
BIT
URW
Unibail Rodamco Westfield
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces